blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4034171

EP4034171 - ANTI-CD47 ANTIBODIES, ACTIVATABLE ANTI-CD47 ANTIBODIES, AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  01.07.2022
Database last updated on 10.07.2024
FormerThe international publication has been made
Status updated on  03.04.2021
Formerunknown
Status updated on  20.10.2020
Most recent event   Tooltip24.04.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
Cytomx Therapeutics Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
[2022/31]
Inventor(s)01 / MEI, Li
c/o CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
02 / FLANDEZ, Jeanne Grace
c/o CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
03 / DANIEL, Dylan
c/o CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
04 / TIPTON, Kimberly Ann
c/o CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
05 / HOSTETTER, Daniel Robert
c/o CytomX Therapeutics, Inc.
151 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080 / US
 [2022/31]
Representative(s)Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[2022/31]
Application number, filing date20789345.423.09.2020
[2022/31]
WO2020US52332
Priority number, dateUS201962904534P23.09.2019         Original published format: US 201962904534 P
[2022/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021061867
Date:01.04.2021
Language:EN
[2021/13]
Type: A1 Application with search report 
No.:EP4034171
Date:03.08.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 01.04.2021 takes the place of the publication of the European patent application.
[2022/31]
Search report(s)International search report - published on:EP01.04.2021
ClassificationIPC:A61K47/68, C07K16/28
[2022/31]
CPC:
C07K16/2803 (EP); A61K47/6849 (EP); A61K47/6891 (EP);
A61K2039/505 (EP); C07K2317/24 (EP); C07K2317/33 (EP);
C07K2317/72 (EP); C07K2317/73 (EP); C07K2317/76 (EP);
C07K2317/92 (EP); C07K2317/94 (EP); C07K2319/50 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/31]
TitleGerman:ANTI-CD47-ANTIKÖRPER, AKTIVIERBARE ANTI-CD47-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON[2022/31]
English:ANTI-CD47 ANTIBODIES, ACTIVATABLE ANTI-CD47 ANTIBODIES, AND METHODS OF USE THEREOF[2022/31]
French:ANTICORPS ANTI-CD47, ANTICORPS ANTI-CD47 ACTIVABLES, ET LEURS MÉTHODES D'UTILISATION[2022/31]
Entry into regional phase29.03.2022National basic fee paid 
29.03.2022Designation fee(s) paid 
29.03.2022Examination fee paid 
Examination procedure29.03.2022Amendment by applicant (claims and/or description)
29.03.2022Examination requested  [2022/31]
29.03.2022Date on which the examining division has become responsible
15.11.2022Loss of particular rights, legal effect: Claims
06.12.2022Despatch of communication of loss of particular rights: Claims {1}
23.04.2024Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time
Fees paidRenewal fee
29.03.2022Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
30.09.202304   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2016014974  (CYTOMX THERAPEUTICS INC [US]) [A] 1-106 * examples 1-19; claims 1-118 *;
 [A]WO2016179285  (CYTOMX THERAPEUTICS INC [US]) [A] 1-106 * examples 1-20; claims 1-100 *;
 [XI]WO2019034895  (ULTRAHUMAN FOUR LTD [GB]) [X] 1,4,5,100-102 * page 47 - page 55; claims 1-34 * [I] 2,3,6-99,103-106;
 [E]WO2020229553  (ULTRAHUMAN SIX LTD [GB]) [E] 6-106* claims 1-72 *;
 [XI]  - VANESSA BUATOIS ET AL, "Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia", MOLECULAR CANCER THERAPEUTICS, US, (20180509), vol. 17, no. 8, doi:10.1158/1535-7163.MCT-17-1095, ISSN 1535-7163, pages 1739 - 1751, XP055523358 [X] 1,4,5,100-102 * page 1740 - page 1741 * * page 1745, column c2, paragraph last * * page 1747 - page 1749 * [I] 2,3,6-99,103-106

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-17-1095
 [XI]  - RUSS ATLANTIS ET AL, "Blocking "don't eat me" signal of CD47-SIRP[alpha] in hematological malignancies, an in-depth review", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, (20180414), vol. 32, no. 6, doi:10.1016/J.BLRE.2018.04.005, ISSN 0268-960X, pages 480 - 489, XP085546938 [X] 1,4,5,100-102 * the whole document * [I] 2,3,6-99,103-106

DOI:   http://dx.doi.org/10.1016/j.blre.2018.04.005
 [I]  - YANG YUN ET AL, "A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index", BIOTECHNOLOGY LETTERS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, vol. 40, no. 5, doi:10.1007/S10529-018-2535-2, ISSN 0141-5492, (20180329), pages 789 - 795, (20180329), XP036481704 [I] 1-106 * the whole document *

DOI:   http://dx.doi.org/10.1007/s10529-018-2535-2
 [A]  - RANJANA ADVANI ET AL, "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma", NEW ENGLAND JOURNAL OF MEDICINE, US, (20181101), vol. 379, no. 18, doi:10.1056/NEJMoa1807315, ISSN 0028-4793, pages 1711 - 1721, XP055730266 [A] 1-106 * the whole document *

DOI:   http://dx.doi.org/10.1056/NEJMoa1807315
by applicantUS3773919
 US4434156
 US4485045
 US4522811
 US4544545
 US5013556
 US5030719
 US5151510
 WO9411026
 US5330896
 US5648469
 WO2005111082
 WO2009025846
 US7572895
 US7666817
 US7736647
 WO2010081173
 WO2010129609
 US8129503
 US2012282176
 US2013045206
 US2013177579
 US2013216476
 US8563269
 WO2013192546
 WO2014020140
 WO2014026136
 US8663598
 US2014114054
 US2014212423
 WO2014144060
 WO2014189973
 CN106245107
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 878 - 883
    - CHOTHIALESK, J. Mol. Biol., (19870000), vol. 196, pages 901 - 917
    - Nature, (19930000), vol. 361, pages 185 - 87
    - DAVIES et al., Annual Rev Biochem, (19900000), vol. 59, pages 439 - 473
    - LAPLANCHE et al., Nucl. Acids Res., (19860000), vol. 14, page 9081
    - STEC et al., J. Am. Chem. Soc., (19840000), vol. 106, page 6077
    - STEIN et al., Nucl. Acids Res., (19880000), vol. 16, page 3209
    - ZON et al., Anti Cancer Drug Design, (19910000), vol. 6, page 539
    - BOWIE et al., Science, (19910000), vol. 253, pages 164 - 108
    - UHLMANNPEYMAN, Chemical Reviews, (19900000), vol. 90, page 543
    - KILLENLINDSTROM, Jour. Immun., (19840000), vol. 133, pages 1335 - 2549
    - THORNTON, Nature, (19910000), vol. 354, page 105
    - EPSTEIN et al., Proc. Natl. Acad. Sci. USA, (19850000), vol. 82, page 3688
    - BOULWARE et al., "Evolutionary optimization of peptide substrates for proteases that exhibit rapid hydrolysis kinetics", Biotechnol Bioeng, (20100000), vol. 106, no. 3, doi:10.1002/bit.22693, pages 339 - 46, XP055331315

DOI:   http://dx.doi.org/10.1002/bit.22693
    - VITETTA et al., Science, (19870000), vol. 238, page 1098
    - JANSEN et al., Immunological Reviews, (19820000), vol. 62, pages 185 - 216
    - RAMAKRISHNAN, S. et al., Cancer Res, (19840000), vol. 44, pages 201 - 208
    - MITRALAWTON, J. Amer. Chem. Soc., (19790000), vol. 16, pages 3097 - 3110
    - HWANG et al., Proc. Natl Acad. Sci. USA, (19800000), vol. 77, page 4030
    - MARTIN et al., J. Biol. Chem., (19820000), vol. 257, pages 286 - 288
    - BALDRICK P, "Pharmaceutical excipient development: the need for preclinical guidance", Regul. Toxicol Pharmacol., (20000000), vol. 32, no. 2, pages 210 - 8
    - WANG W, "Lyophilization and development of solid protein pharmaceuticals", Int. J. Pharm., (20000000), vol. 203, no. 1-2, doi:10.1016/S0378-5173(00)00423-3, pages 1 - 60, XP002428586

DOI:   http://dx.doi.org/10.1016/S0378-5173(00)00423-3
    - CHARMAN WN, "Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts", J Pharm Sci, (20000000), vol. 89, no. 8, pages 967 - 78, XP008099512
    - POWELL et al., "Compendium of excipients for parenteral formulations", PDA J Pharm Sci Technol, (19980000), vol. 52, pages 238 - 311, XP009119027
    - REMINGTON et al., ELISA: Theory and Practice: Methods in Molecular Biology, Mack Pub. Co., (19950000), vol. 42
    - "Peptide And Protein Drug Delivery", Advances In Parenteral Sciences, M. Dekker, (19910000), vol. 4
    - MARASCO et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 7889 - 7893
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.